Biogen Idec Inc. shares climbed 4.9 percent to a record $223.98 before closing at $223.61, up4.7 percent. The Weston company’s new multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis and Sanofi, Bloomberg News reported, suggesting the treatment may beat sales estimates for the year. Total prescriptions more than doubled during the third week of the launch to 730 from 332 the previous week, according to Wells Fargo & Co.
Biogen Idec gains on new MS drug’s sales
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week